The technology for preclinical testing of antimetastatic and antitumor agents

POD Reference

TOUA20140626002

Summary

A university in Kyiv (Ukraine) offers the technology for preclinical research of antimetastatic and antitumor agents based on the induction of cancer metastasizing into liver. The advantages: short time period for testing, high effectiveness. The university is looking for partners interested in experimental study of novel agents of antimetastatic effect, as well as in research of effectiveness of complex administration of antimetastatic and hepatoprotective agents.

Description

Among all liver cancer types 90% are metastatic. Every third oncological patient, independently of primary tumor, has a metastatic lesion in liver, from 50 % to 75 % of all oncological patients die due to liver metastases. In this connection the development of agents for liver metastatic tumor therapy is an solution of the very urgent problem of health protection.

The organization had developed the technology that allows performing preclinical research of therapy agents.

Technology includes stages mentioned below:

- Generation of the experimental model of metastasizing tumor by inoculation of tumor cells to experimental animals.

Standardized suspension of tumor cells is obtained by the use of conventional technique and injected intrasplenic what provides of 100% of metastases in liver at short notice (on the 14th day);

- Research of antimetastatic and antitumor effect of examined agents.

Examined preparations are injected intravenously, intramuscularly or locally in an area of the tumor growth of experimental animals. The dynamics of tumor growth and metastasis are registered, as well as clinical and immunological parameters in dynamics are evaluated.

The organization is looking for technical and research cooperation for experimental study of novel agents of antimetastatic effect, as well as in research of effectiveness of complex administration of antimetastatic and hepatoprotective agents.

Advantages and Innovations

The main advantages are the following:

- High effectiveness of the method that provides of 100%, metastases in liver of animals.

- Reducing of a research period of anticancer agent.

Stage of Development

Under development/lab tested

IPR status

Patents granted

Comments Regarding IPR Status

Patent of Ukraine, 2013

Profile Origin

National R&D programme

Deadline Date

7/25/2015 12:00:00 AM

Technology Keywords

006001016 Pharmaceutical Products / Drugs
006002005 In vitro Testing, Trials

Market Keywords

005003002 Pharmaceuticals/fine chemicals
009003007 Other services (not elsewhere classified)

Type and Role of Partner Sought

Type of partner sought: Investors, research and medical companies in oncology, pharmaceutics, veterinary medicine

Specific area of activity of the partner: preclinical research of antimetastatic and antitumor agents

Task to be performed by the partner sought: partners would be interested in collaboration in preclinical research of antimetastatic and antitumor agents, antitumor agents of general purpose or target antitumor action, in experimental study of novel agents of antimetastatic effect, as well as in research of effectiveness of complex administration of antimetastatic and hepatoprotective agents.

Type and Size of Partner Sought

R&D Institution
SME 11-50
University

Type of Partnership Considered

Research cooperation agreement
Technical cooperation agreement